Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Al B Benson

Showing results (81-90 of 350) with videos related to

Pageof 35
Sort By:
Oncology (Williston Park, N.Y.)|October 23, 2003
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardiaJ Randolph Hecht, Charles D Blanke, Al B Benson, et al.
AJR. American Journal of Roentgenology|June 25, 2011
Response to treatment series: part 2, tumor response assessment--using new and conventional criteriaVahid Yaghmai, Frank H Miller, Pedram Rezai, et al.
Academic Radiology|June 6, 2020
Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary InvestigationAydin Eresen, Jia Yang, Junjie Shangguan, et al.
Current Medical Research and Opinion|July 27, 2018
Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USAMichael S Broder, Beilei Cai, Eunice Chang, et al.
Cancer Journal (Sudbury, Mass.)|June 21, 2002
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296Scott Wadler, Carlos Brain, Paul Catalano, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Refining docetaxel-containing therapy for gastric cancerNushmia Z Khokhar, Yixing Jiang, Al B Benson, et al.
The Oncologist|March 2, 2017
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic <i>KRAS</i> Mutant Colorectal AdenocarcinomaJ Randolph Hecht, Al B Benson, Dmitry Vyushkov, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 22, 2013
Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview studyKaren Kaiser, Rajiv Mallick, Zeeshan Butt, et al.
Pancreas|March 6, 2020
Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes StudyAl B Benson, Jonathan Strosberg, Vijay N Joish, et al.
Oncology|March 7, 2018
Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database AnalysisMichael S Broder, Beilei Cai, Eunice Chang, et al.
Pageof 35

Showing results (81-90 of 350) with videos related to

Sort By:
Pageof 35
Oncology (Williston Park, N.Y.)|October 23, 2003
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardiaJ Randolph Hecht, Charles D Blanke, Al B Benson, et al.
AJR. American Journal of Roentgenology|June 25, 2011
Response to treatment series: part 2, tumor response assessment--using new and conventional criteriaVahid Yaghmai, Frank H Miller, Pedram Rezai, et al.
Academic Radiology|June 6, 2020
Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary InvestigationAydin Eresen, Jia Yang, Junjie Shangguan, et al.
Current Medical Research and Opinion|July 27, 2018
Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USAMichael S Broder, Beilei Cai, Eunice Chang, et al.
Cancer Journal (Sudbury, Mass.)|June 21, 2002
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296Scott Wadler, Carlos Brain, Paul Catalano, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Refining docetaxel-containing therapy for gastric cancerNushmia Z Khokhar, Yixing Jiang, Al B Benson, et al.
The Oncologist|March 2, 2017
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic <i>KRAS</i> Mutant Colorectal AdenocarcinomaJ Randolph Hecht, Al B Benson, Dmitry Vyushkov, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 22, 2013
Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview studyKaren Kaiser, Rajiv Mallick, Zeeshan Butt, et al.
Pancreas|March 6, 2020
Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes StudyAl B Benson, Jonathan Strosberg, Vijay N Joish, et al.
Oncology|March 7, 2018
Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database AnalysisMichael S Broder, Beilei Cai, Eunice Chang, et al.
Pageof 35